CIK 0001755237 · Non-accelerated filer<br>Smaller reporting company
Korsana Biosciences, Inc.
Sign in to watch- Ticker
- KRSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 831895370
- Phone
- (781) 516-2325
- Business address
- 203 CRESCENT STREET, BLDGS. #3/3A/4, SUITE 503, WALTHAM, MA, 02453
- Former names
- Cyclerion Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 1 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-03 | Hecht Peter M Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +52,950 | 52,950 | ||
| 2021-12-09 | Busch Andreas Chief Scientific Officer | Grant or award · Employee Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2021-12-09 | Gjino Anjeza Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2021-12-09 | Gault Cheryl Chief Operating Officer | Grant or award · Employee Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2021-06-24 | Lovell Stephanie Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-24 | Fanucci Marsha Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-24 | Isacson Ole Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-24 | Churchwell Kevin Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-24 | Mendelsohn Michael Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-24 | CONRADES GEORGE H Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-24 | DESOUZA ERROL B Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-24 | MCGUIRE TERRANCE Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2021-06-03 | Hecht Peter M Chief Executive Officer | Purchase | +823,170 | $3.28 | $2.7M | 2,047,698 |
| 2021-06-03 | Slate Path Capital LP 10% owner | Purchase | +961,538 | $3.12 | $3.0M | 7,157,601 |
| 2021-06-03 | MCGUIRE TERRANCE Director | Purchase | +92,831 | $3.12 | $290K | 697,313 |
| 2021-06-03 | MCGUIRE TERRANCE Director | Purchase | +3,322 | $3.12 | $10K | 24,957 |
| 2021-05-06 | Hecht Peter M Chief Executive Officer | Purchase | +302,000 | $2.43 | $734K | 1,224,528 |
| 2021-05-05 | Hecht Peter M Chief Executive Officer | Purchase | +398,001 | $2.53 | $1.0M | 922,528 |
| 2021-05-04 | Hecht Peter M Chief Executive Officer | Purchase | +300,000 | $2.29 | $687K | 524,527 |
| 2021-02-25 | Gjino Anjeza Chief Financial Officer | Sale | −1,824 | $4.00 | $7K | 31,599 |
Page 3 of 9 · 167 trades